Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...

Wegovy is the first GLP-1 drug approved to treat adults with metabolic dysfunction-associated steatohepatitis (MASH). An ...

A shorter course of prophylactic antibiotics, or even no course at all, appeared to be noninferior to longer courses in ...

Serious infections significantly increase the mortality risk among adults with chronic liver disease, including those without cirrhosis.

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

One of the challenges with liver disease is that it can be a silent threat. In its early stages, it may cause only vague ...

In hospitalized patients with acute kidney injury and liver cirrhosis, baseline and peak levels of serum cystatin C can ...

In moderate to severe Crohn's disease, a network meta-analysis suggested that TNF inhibitor-based therapy was the most ...

Alcoholic cirrhosis isn’t something that appears overnight. It is the tragic result of long-term alcohol use that scars and weakens the liver, stopping it from doing vital tasks.

Cirrhosis or fibrosis of the liver can occur due to several liver-related diseases and conditions, such as hepatitis, non-alcoholic fatty liver disease, and excessive alcohol consumption.

FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated ...